A combination of two types of blood pressure-lowering drugs—an angiotensin-converting enzyme inhibitor plus an angiotensin-receptor blocker, added to enzyme replacement therapy with agalsidase-beta —is the first treatment shown to stop progressive loss of kidney function in patients with severe kidney involvement due to the rare genetic disorder Fabry disease, reports a study in the September Journal of American Society of Nephrology.
Get the full story...
